Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

1.6K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.6K
Drug Absorption: Factors Affecting GI Absorption01:19

Drug Absorption: Factors Affecting GI Absorption

6.7K
The process of oral drug absorption can be influenced by several factors. Weakly acidic drugs tend to be absorbed more readily from the stomach due to their nonionized state. However, absorption may be less efficient in the upper intestine, where drugs are often ionized. Interestingly, despite the stomach's apparent advantage for drug absorption, its mucous layer can hinder diffusion. Its surface area is also smaller than the intestine's, which can further slow down the absorption rate.
6.7K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.1K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.1K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry01:20

Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry

634
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
634
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

575
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
575
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transitioning Adolescents and Young Adults With Neurogastroenterology and Motility Disorders to Adult Care. Current Practices and Challenges in North America.

Neurogastroenterology and motility·2026
Same author

Evaluating linaclotide for the treatment of irritable bowel syndrome with constipation in children and adolescents.

Expert opinion on pharmacotherapy·2026
Same author

Menstrual-Associated Gastrointestinal Symptoms and Their Impact on IBS Diagnosis in Adolescents.

Neurogastroenterology and motility·2026
Same author

CBT for Pediatric Functional Abdominal Pain: Time to Rethink Traditional Assumptions?

The American journal of gastroenterology·2026
Same author

Knowledge Does Not Translate Into Diagnostic Restraint: Application of Rome-Based IBS Diagnosis Among Medical Students in Latin America.

Neurogastroenterology and motility·2026
Same author

Evaluating linaclotide for the treatment of functional constipation in children and adolescents.

Expert opinion on pharmacotherapy·2026

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.1K

Gastrointestinal Pharmacology.

Miguel Saps1, Adrian Miranda2

  • 1Division of Pediatric Gastroenterology, Hepatology and Nutrition, Nationwide Children's Hospital, Columbus, OH, USA. miguel.saps@nationwidechildrens.org.

Handbook of Experimental Pharmacology
|February 26, 2017
PubMed
Summary
This summary is machine-generated.

Limited evidence supports most medications for pediatric functional abdominal pain disorders (FAPDs). More rigorous trials are essential to determine effective pharmacological treatments for children with FAPDs.

Keywords:
ChildrenClinical trialsFunctional abdominal pain disordersIrritable bowel syndromeTreatment

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.8K
An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

9.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.1K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.8K
An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products
14:54

An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products

Published on: October 20, 2018

9.0K

Area of Science:

  • Pediatric Gastroenterology
  • Pharmacology
  • Clinical Trials

Background:

  • Functional abdominal pain disorders (FAPDs) are common in children.
  • Current pharmacological treatments often lack robust evidence in pediatric populations.
  • Treatment decisions frequently rely on adult data or empirical approaches.

Purpose of the Study:

  • To review the available evidence for medications used in treating pediatric FAPDs.
  • To identify gaps in research and highlight the need for pediatric-specific clinical trials.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) and other studies.
  • Analysis of medication efficacy and safety data in children with FAPDs.
  • Comparison of findings with adult treatment guidelines.

Main Results:

  • Peppermint oil, trimebutine, and drotaverine showed benefit in single RCTs.
  • Conflicting data exist for amitriptyline; citalopram and rifaximin showed no benefit in children.
  • Evidence for gabapentin, pregabalin, linaclotide, lubiprostone, and eluxadoline in pediatric FAPDs is lacking.

Conclusions:

  • Substantial data gaps exist for most FAPD medications in children.
  • More high-quality, randomized, placebo-controlled trials are urgently needed.
  • Evidence-based pharmacological strategies for pediatric FAPDs require further investigation.